Actinia

Executive Summary

Actinia, founded in 2015 and headquartered in San Diego, is pioneering the development of advanced radiation detector materials using halide perovskites. These materials promise to significantly enhance the performance of medical imaging and security scanning devices by enabling higher resolution or lower radiation doses. The company's core mission is to improve the safety, efficiency, and security of nuclear technologies across medical, industrial, and defense applications. Actinia's technology addresses critical limitations of conventional detectors, such as scintillators and semiconductors, by offering superior energy resolution, lower manufacturing costs, and scalability to large-area sensors. This positions the company to capture value in the growing market for radiation detection in healthcare (e.g., nuclear medicine, PET/CT) and homeland security (e.g., cargo scanning, border security). As a private, pre-revenue company, Actinia has not publicly disclosed funding rounds or commercial partnerships. However, its underlying technology has attracted interest from both academic and industry players due to the versatility of perovskite materials. The company likely faces typical startup challenges of scaling material synthesis, integrating detectors into OEM devices, and navigating regulatory pathways. Near-term milestones include prototype validation with potential partners, followed by initial funding to support pilot manufacturing. If successful, Actinia could disrupt the radiation detection market, currently dominated by established players. The company's progress remains speculative without recent disclosures, but its novel material approach and clear use cases warrant moderate attention.

Upcoming Catalysts (preview)

• Q3 2026Series A funding round closing60% success
• Q4 2026Initial prototype demonstration with a medical imaging partner45% success
• Q2 2026Publication of performance data in a peer-reviewed journal75% success